mRNA Vaccine Development against Tropical Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 3032

Special Issue Editor


E-Mail Website
Guest Editor
Baylor College of Medicine, Houston, TX, USA
Interests: Immunology; neglected tropical diseases; Chagas; mRNA vaccines; flow cytometry; host–parasite interaction; macrophages

Special Issue Information

Dear Colleagues,

At least one billion people are still affected by Tropical Diseases in Africa, Asia, and Latin America. Affecting the poorest areas in the regions, the most effective intervention to prevent infectious disease is vectorial control and improvements to sanitation, water quality, and hygiene, but these interventions are not enough. Vaccination is the most effective way to prevent infectious diseases. However, complex pathogens such as Plasmodium (Malaria), Trypanosoma cruzi (Chagas), Trypanosoma brucei (African Sleeping Sickness), Leishmania, Zika, and others have not been yet effectively tackled with conventional vaccines. mRNA vaccines for COVID-19 demonstrated how plasticity can accelerate the development of new vaccines for complex diseases. 

We are pleased to announce this Special Issue on “mRNA Vaccine Development against Tropical Diseases”. The issue centers on (1) screening and identifying suitable vaccine candidates using novel in vitro techniques and assays, which allows for a better understanding of the biological and immunological complexities of pathogens, infection, and disease; (2) progress in nucleic acid delivery technology and how it improves vaccine potency and safety; and (3) the regulatory and manufacturer challenges to implementations in the regions (Asia, Africa, Latin America).

Dr. Cristina Poveda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mRNA vaccine
  • Chagas disease
  • tropical diseases
  • immunology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3695 KiB  
Article
A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces Potent Chikungunya and Ross River Virus Specific Immune Responses
by Christin Schmidt, Florian D. Hastert, Julia Gerbeth, Tim Beissert, Ugur Sahin, Mario Perkovic and Barbara S. Schnierle
Vaccines 2022, 10(9), 1374; https://doi.org/10.3390/vaccines10091374 - 23 Aug 2022
Cited by 8 | Viewed by 2655
Abstract
Alphaviruses such as the human pathogenic chikungunya virus (CHIKV) and Ross River virus (RRV) can cause explosive outbreaks raising public health concerns. However, no vaccine or specific antiviral treatment is yet available. We recently established a CHIKV vaccine candidate based on trans-amplifying RNA [...] Read more.
Alphaviruses such as the human pathogenic chikungunya virus (CHIKV) and Ross River virus (RRV) can cause explosive outbreaks raising public health concerns. However, no vaccine or specific antiviral treatment is yet available. We recently established a CHIKV vaccine candidate based on trans-amplifying RNA (taRNA). This novel system consists of a replicase-encoding mRNA and a trans-replicon (TR) RNA encoding the antigen. The TR-RNA is amplified by the replicase in situ. We were interested in determining whether multiple TR-RNAs can be amplified in parallel and if, thus, a multivalent vaccine candidate can be generated. In vitro, we observed an efficient amplification of two TR-RNAs, encoding for the CHIKV and the RRV envelope proteins, by the replicase, which resulted in a high antigen expression. Vaccination of BALB/c mice with the two TR-RNAs induced CHIKV- and RRV-specific humoral and cellular immune responses. However, antibody titers and neutralization capacity were higher after immunization with a single TR-RNA. In contrast, alphavirus-specific T cell responses were equally potent after the bivalent vaccination. These data show the proof-of-principle that the taRNA system can be used to generate multivalent vaccines; however, further optimizations will be needed for clinical application. Full article
(This article belongs to the Special Issue mRNA Vaccine Development against Tropical Diseases)
Show Figures

Figure 1

Back to TopTop